MediRama Signs Strategic Collaboration Agreement with TD2 Oncology, a global, full service CRO specializing in Oncology to Support Global Expansion of Korean Biotech Firms

MediRama, a Korean CRO specialized in oncology, announced on 27th of June 2025 that it has entered into a clinical development collaboration agreement with TD2 Oncology, a global CRO specializing in oncology based in the United States.

This strategic collaboration is designed to provide an integrated clinical development strategy — from protocol development and early-phase trials to FDA registration — for Korean biotech companies and startups seeking to enter the U.S. market.

Leveraging its clinical trial operations expertise in Korea and the broader Asia region, MediRama has supported domestic biotech companies in designing clinical strategies, initiating Phase 1 oncology trials, and establishing U.S. market linkages.

Through this agreement, the two companies plan to offer tailored joint services to Korean firms developing oncology drugs for the U.S. market. These services will include access to hospital and site networks, expert investigators, and regulatory strategy consulting in both the US and South Korea.

Dr. Hanlim Moon, CEO of MediRama, stated, “Successful clinical trials in the U.S. serve as a key inflection point for fundraising and technology licensing. We are committed to providing practical solutions to help Korean biotech startups enter the U.S. clinical trial market quickly and efficiently.”

“This agreement marks the beginning of a powerful strategic collaboration between two leaders in oncology drug development and clinical trial operational excellence – we are committed to a shared mission of advancing therapies and transforming patient outcomes” said Steve Gately, PhD, Chief Executive Officer of TD2 Oncology.

With this partnership, MediRama further solidifies its role as a strategic global development partner for Korean oncology drug developers.

About MediRama

MediRama is an oncology-focused CRO led by Dr. Hanlim Moon. The company has built a strong track record of delivering essential consulting services for oncology drug development by leveraging its in-house expert pool and extensive domestic and international oncology expert networks. Recently, MediRama has expanded its capabilities to include full clinical CRO services. With a robust Medical Science team and experienced Project Management team, MediRama provides customized services to clients targeting the global market — from Clinical Development Plan (CDP) design to full-scope clinical trial execution.

For more information, visit: www.medirama.co.kr

About TD2 Oncology

TD2 is a full service global CRO with deep expertise in complex oncology trials across a broad range of drug classes including radiopharmaceuticals. Founded by Dr. Daniel Von Hoff in 2003, TD2 is dedicated to advancing oncology drug development with exceptional scientific insight to operational efficiency and strategic execution. Leveraging decades of specialized experience, TD2 offers strategic tailored solutions to accelerate the path from scientific discoveries to life-changing patient therapies.  TD2 has a significant track record of executing successful early and mid-stage oncology clinical trials, leveraging its network of oncology experts to navigate the challenges of working with these compounds.

For more information, visit: www.td2inc.com.